AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 108_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 34_CD Company_NN information_NN Company_NN Balance_NNP Sheet_NNP 2003_CD 2002_CD At_IN 31_CD December_NNP Notes_NNP $_$ m_CD $_$ m_CD Fixed_VBN assets_NNS Fixed_VBN asset_NN investments_NNS 34_CD 6,940_CD 7,236_CD Current_JJ assets_NNS Debtors_NNS other_JJ 7_CD Debtors_NNS amounts_VBZ owed_VBN by_IN subsidiaries_NNS 25,339_CD 27,104_CD 25,346_CD 27,104_CD Total_JJ assets_NNS 32,286_CD 34,340_CD Creditors_NNS due_JJ within_IN one_CD year_NN Non-trade_JJ creditors_NNS 34_CD 3,120_CD 2,961_CD Net_JJ current_JJ assets_NNS 22,226_CD 24,143_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 29,166_CD 31,379_CD Creditors_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN Loans_NNPS owed_VBD to_TO subsidiaries_NNS 34 295 295_CD Net_JJ assets_NNS 28,871_CD 31,084_CD Capital_NN and_CC reserves_NNS Called-up_JJ share_NN capital_NN 35 423 429_CD Share_NN premium_NN account_NN 34 449 403_CD Capital_NNP redemption_NN reserve_NN 34_CD 23_CD 16_CD Other_JJ reserves_NNS 34_CD 1,841_CD 1,841_CD Profit_NN and_CC loss_NN account_NN 34_CD 26,135_CD 28,395_CD Shareholders_NNS funds_NNS equity_NN interests_NNS 28,871_CD 31,084_CD The_DT Financial_NNP Statements_NNP on_IN pages_NNS 62_CD to_TO 123_CD were_VBD approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS on_IN 29_CD January_NNP 2004_CD and_CC were_VBD signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: Sir_NNP Tom_NNP McKillop_NNP Jonathan_NNP Symonds_NNP Director_NNP Director_NNP AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2003_CD 109_CD 34_CD Company_NN information_NN continued_VBD Deferred_JJ taxation_NN The_DT parent_NN company_NN had_VBD no_DT deferred_JJ tax_NN assets_NNS or_CC liabilities_NNS actual_JJ or_CC potential_JJ at_IN 31_CD December_NNP 2003_CD ._.
Investments_NNP in_IN subsidiaries_NNS Fixed_VBN asset_NN investments_NNS Shares_NNP Loans_NNP Total_NNP $_$ m_CD $_$ m_CD $_$ m_CD Cost_NN at_IN beginning_NN of_IN year_NN 6,645_CD 591_CD 7,236_CD Additions_NNPS Disposals_NNPS and_CC other_JJ movements_NNS 296_CD 296_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2003_CD 6,645_CD 295_CD 6,940_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2002_CD 6,645_CD 591_CD 7,236_CD Non-trade_JJ creditors_NNS 2003_CD 2002_CD $_$ m_CD $_$ m_CD Amounts_NNS due_JJ within_IN one_CD year_NN Short_JJ term_NN borrowings_NNS unsecured_JJ 3_CD 3_CD Other_JJ creditors_NNS 154_CD 50_CD Amounts_NNS owed_VBN to_TO subsidiaries_NNS 2,049_CD 2,100_CD Dividends_NNS to_TO shareholders_NNS 914_CD 808_CD 3,120_CD 2,961_CD Loans_NNPS owed_VBD to_TO subsidiaries_NNS Repayment_NN 2003_CD 2002_CD Dates_NNPS $_$ m_CD $_$ m_CD Loans_JJ unsecured_JJ US_NNP dollars_NNS 6.58_CD %_NN loan_NN 2003_CD 295_CD 7.2_CD %_NN loan_NN 2023 295 295_CD Total_JJ loans_NNS 295_CD 590_CD Loans_NNPS or_CC instalments_NNS thereof_RB are_VBP repayable_JJ :_: After_IN five_CD years_NNS from_IN balance_NN sheet_NN date_NN 295_CD 295_CD From_IN two_CD to_TO five_CD years_NNS From_IN one_CD to_TO two_CD years_NNS Total_JJ unsecured_JJ 295_CD 295_CD Total_JJ due_JJ within_IN one_CD year_NN 295_CD Total_JJ loans_NNS 295_CD 590_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 110_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 34_CD Company_NN information_NN continued_VBD Share_NNP Capital_NNP Profit_NNP premium_NN redemption_NN Other_JJ and_CC loss_NN 2003_CD 2002_CD Reserves_NNS account_VBP reserve_NN reserves_NNS account_VBP Total_JJ Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD At_IN beginning_NN of_IN year_NN 403_CD 16_CD 1,841_CD 28,395_CD 30,655_CD 32,873_CD Net_JJ profit_NN for_IN the_DT year_NN 244 244 102_CD Dividends_NNPS 1,350_CD 1,350_CD 1,206_CD Share_NN re-purchase_NN 7_CD 1,154_CD 1,147_CD 1,183_CD Share_NN premiums_NNS 46_CD 46_CD 69_CD At_IN end_NN of_IN year_NN 449_CD 23_CD 1,841_CD 26,135_CD 28,448_CD 30,655_CD Distributable_JJ reserves_NNS at_IN end_NN of_IN year_NN 489_CD 1,103_CD 1,592_CD 2,057_CD As_IN permitted_VBN by_IN section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT Company_NN has_VBZ not_RB presented_VBN its_PRP$ profit_NN and_CC loss_NN account_NN ._.
At_IN 31_CD December_NNP 2003_CD $_$ 25,032_CD m_NN 31_CD December_NNP 2002_CD $_$ 26,781_CD m_NN of_IN the_DT profit_NN and_CC loss_NN account_NN reserve_NN was_VBD not_RB available_JJ for_IN distribution_NN ._.
The_DT majority_NN of_IN this_DT non-distributable_JJ amount_NN relates_VBZ to_TO profit_VB arising_VBG on_IN the_DT sale_NN of_IN Astra_NNP AB_NNP to_TO a_DT subsidiary_NN in_IN 1999_CD ,_, which_WDT becomes_VBZ distributable_JJ as_IN the_DT underlying_VBG receivable_NN is_VBZ settled_VBN in_IN cash_NN ._.
During_IN 2003_CD ,_, $_$ 1,749_CD m_NN of_IN the_DT profit_NN was_VBD realized_VBN by_IN repayment_NN ._.
Subsequent_JJ to_TO the_DT year_NN end_NN a_DT further_JJ $_$ 1,124_CD m_NN was_VBD repaid_VBN on_IN 27_CD January_NNP 2004_CD resulting_VBG in_IN additional_JJ distributable_JJ reserves_NNS not_RB included_VBD in_IN the_DT figures_NNS above_IN ._.
Included_VBN in_IN other_JJ reserves_NNS is_VBZ a_DT special_JJ reserve_NN of_IN $_$ 157m_CD ,_, arising_VBG on_IN the_DT redenomination_NN of_IN share_NN capital_NN in_IN 1999_CD ._.
2003_CD 2002_CD Reconciliation_NNP of_IN movement_NN in_IN shareholders_NNS funds_NNS $_$ m_CD $_$ m_CD Shareholders_NNS funds_NNS at_IN beginning_NN of_IN year_NN 31,084_CD 33,309_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN 244_CD 102_CD Dividends_NNPS 1,350_CD 1,206_CD Issues_NNS of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 47_CD 69_CD Re-purchase_NN of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 1,154_CD 1,190_CD Net_JJ reduction_NN in_IN shareholders_NNS funds_NNS 2,213_CD 2,225_CD Shareholders_NNS funds_NNS at_IN end_NN of_IN year_NN 28,871_CD 31,084_CD
